Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 388Colorectal Neoplasms 307Rectal Neoplasms 225Stomach Neoplasms 206Pancreatic Neoplasms 137Neoplasm Metastasis 121Colonic Neoplasms 93Neoplasms 85Triple Negative Breast Neoplasms 63Esophageal Neoplasms 57Biliary Tract Neoplasms 37Nasopharyngeal Carcinoma 36Cholangiocarcinoma 31Adenocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Gastrointestinal Neoplasms 18Brain Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Ovarian Neoplasms 14Colorectal Cancer Metastatic 14Breast Neoplasms, Male 14

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER-2 Gene Amplification × Capecitabine × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡